Clinical Trials

To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.

For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)

Learn more about research and clinical trials at Valley.

Clear All

A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Principal Investigator(s): Kevin Wood, MD

Status: Open and enrolling

A081801 Alchemist

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Principal Investigator(s): Jason W. Suh, MD

Status: Open and enrolling

AB154CSP0002 – Arcus

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Principal Investigator(s): Eli Kirshner, MD

Status: Open and enrolling

ASTEFANIA

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Principal Investigator(s): Amanda J. Podolski, MD

Status: Open and enrolling

CAPITELLO - 291

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

Principal Investigator(s): Eleonora Teplinsky, MD

Status: Open and enrolling

DRAMMATIC (S1803)

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Principal Investigator(s): Jason W. Suh, MD

Status: Open and enrolling

Duo-E GOG-3041

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Principal Investigator(s): Eleonora Teplinsky, MD

Status: Closed to Enrollment, No Patients in Follow-Up

GI005 - COBRA

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Principal Investigator(s): Kevin Wood, MD

Status: Open and enrolling

GLORIOSA

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA).

Principal Investigator(s): Eleonora Teplinsky, MD

Status: Open and enrolling

GOG 3026

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum

Principal Investigator(s): Eleonora Teplinsky, MD

Status: Closed to Enrollment, No Patients in Follow-Up